RxDoctor Payments Data

Brennan Haraden, MD

Cardiovascular Disease · Louisville, KYNPI 1063410355

Payments from drug & device makers

$2,144in general payments, 2019–2025

Across 133 payments — averaging $16.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$344
  • Novartis$247
  • Novo Nordisk$180
  • E.r. Squibb & Sons, L.L.C.$177
  • Johnson & Johnson$157
  • Medtronic$146
  • plus $893 from 21 others

What the payments were for

  • Food & beverage$2,10598%
  • Education$392%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,144 in reported general payments places this provider in the 40th percentile of 258 cardiovascular disease providers in Kentucky.

See all cardiovascular disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$232,263
Medicare patients
1,703
Services billed
3,781

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban444$430,725
XareltoRivaroxaban201$207,998
EntrestoSacubitril/Valsartan30$29,108
Repatha SyringeEvolocumab25$16,881
Metoprolol Succinate485$6,200
EdarbiAzilsartan Medoxomil14$3,415
Warfarin Sodium129$1,508
Digoxin59$1,467
Potassium Chloride47$1,025
Atorvastatin Calcium125$1,021
ClopidogrelClopidogrel Bisulfate124$993
Carvedilol140$964
Isosorbide Mononitrate ErIsosorbide Mononitrate63$903
Metoprolol Tartrate116$860
Diltiazem 24hr Er (Cd)Diltiazem Hcl35$696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$344$430,725444 claims
Johnson & JohnsonXarelto$157$207,998201 claims
NovartisEntresto$247$29,10830 claims
Arbor Pharmaceuticals, Inc.Edarbi$14$3,41514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 258 cardiovascular disease providers in Kentucky.

Other cardiovascular disease in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →